Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Champions Oncology (CSBR) over the last 15 years, with Q4 2025 value amounting to $12.3 million.

  • Champions Oncology's Current Deferred Revenue rose 2072.41% to $12.3 million in Q4 2025 from the same period last year, while for Oct 2025 it was $12.3 million, marking a year-over-year increase of 2072.41%. This contributed to the annual value of $15.4 million for FY2025, which is 2769.14% up from last year.
  • According to the latest figures from Q4 2025, Champions Oncology's Current Deferred Revenue is $12.3 million, which was up 2072.41% from $14.4 million recorded in Q3 2025.
  • Champions Oncology's Current Deferred Revenue's 5-year high stood at $15.4 million during Q2 2025, with a 5-year trough of $5.5 million in Q3 2021.
  • Over the past 5 years, Champions Oncology's median Current Deferred Revenue value was $11.1 million (recorded in 2022), while the average stood at $10.8 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 9859.51% in 2022, then crashed by 2119.06% in 2024.
  • Quarter analysis of 5 years shows Champions Oncology's Current Deferred Revenue stood at $6.1 million in 2021, then soared by 82.4% to $11.2 million in 2022, then grew by 15.94% to $13.0 million in 2023, then fell by 21.19% to $10.2 million in 2024, then rose by 20.72% to $12.3 million in 2025.
  • Its last three reported values are $12.3 million in Q4 2025, $14.4 million for Q3 2025, and $15.4 million during Q2 2025.